| __timestamp | Intra-Cellular Therapies, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 60987000 |
| Thursday, January 1, 2015 | 139626 | 125542000 |
| Friday, January 1, 2016 | 93831530 | 210460000 |
| Sunday, January 1, 2017 | 79419009 | 275119000 |
| Monday, January 1, 2018 | 368673 | 409539000 |
| Tuesday, January 1, 2019 | 477121 | 547758000 |
| Wednesday, January 1, 2020 | 1895029 | 736300000 |
| Friday, January 1, 2021 | 8034589 | 904200000 |
| Saturday, January 1, 2022 | 20443000 | 1080300000 |
| Sunday, January 1, 2023 | 33745000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, understanding cost structures is crucial. Vertex Pharmaceuticals Incorporated and Intra-Cellular Therapies, Inc. offer a fascinating comparison. Over the past decade, Vertex has consistently outpaced Intra-Cellular in terms of cost of revenue, reflecting its expansive operations and market reach. In 2023, Vertex's cost of revenue was approximately 37 times higher than Intra-Cellular's, highlighting its significant scale.
From 2014 to 2023, Vertex's cost of revenue grew by over 1,900%, while Intra-Cellular's increased by around 59%. This stark contrast underscores Vertex's aggressive growth strategy and its ability to manage larger production costs. Meanwhile, Intra-Cellular's more modest increase suggests a focus on niche markets or a more conservative expansion approach.
This data not only reflects the companies' financial strategies but also offers insights into their market positioning and future potential.
Cost Insights: Breaking Down AbbVie Inc. and Intra-Cellular Therapies, Inc.'s Expenses
Amgen Inc. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and United Therapeutics Corporation
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Viatris Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Jazz Pharmaceuticals plc
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Grifols, S.A.
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Intra-Cellular Therapies, Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.